Monday, November 10, 2025

Hexo: Canaccord Lowers Price Target Following Poor Execution

On Monday, Hexo Corp (TSX: HEXO) (NYSE: HEXO) reported their fiscal third-quarter estimates which missed consensus estimates significantly. HEXO reported revenues of $22.7 million, a measly 2% increase year over year and a ~31% decrease quarter over quarter. Gross profit came in at $4.38 million, and had the same fate as revenue, cratering 61.3% quarter over quarter.

Many analysts have come out and lowered their targets and ratings on the company. ATB, Alliance, CIBC, Stifel-GMP, and Canaccord lowered their 12-month price targets bringing the consensus 12-month price target to C$8.43, down from C$9.47 from before the release. The company has 12 analysts covering the stock with three analysts having buy ratings, eight analysts have hold ratings and one analyst has a strong sell rating. The street high comes from Alliance Global with a C$12 price target while the lowest comes in at C$5.97.

In Canaccord’s note, they lowered their 12-month price target to C$7.00 from C$9.00 and reiterated their hold rating on the name. Matt Bottomley says that this quarter “represented a step back with respect to the company’s execution in its core legacy business,” even though the recent M&A puts the company in a top-three market share position.

For this quarter, the company reported revenues $10 million lower than Canaccord’s estimates. This is concerning to Bottomley due to the company seeing sales in its core market drop by $5.2 million and the company having issues with its production of hash products during the quarter. BUT the company boasted a leading market share of 46% in beverages!

Bottomley warns that the volatility in LP’s revenue might continue as “the saturated Canadian cannabis landscape continues to evolve,” and believes that this is a very high risk to the LP’s fundamentals.

Below you can see Canaccord’s updated full-year 2021 and 2022 estimates.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Is Altamira Gold Sitting On Brazil’s Next Big Gold Discovery?

Coeur Mining: The $7 Billion Acquisition Of New Gold

Fresnillo Steps Out Of Mexico With $780 Million Probe Gold Buyout

Recommended

ESGold Completes Mill Building Construction, Final Equipment Procurement Underway

PTX Metals Compiles Geophysical Data For W2 Project Following Magnetic Survey

Related News

Medipharm Labs Sees Canaccord Drop Price Target To $0.75

On May 17th, MediPharm Labs (TSX: LABS) Labs reported their first-quarter financials. The company announced...

Tuesday, May 18, 2021, 05:32:00 PM

Eight Capital Initiates Coverage On Field Trip Health With $10.20 Price Target

Earlier this week, Eight Capital launched coverage on a basket of psychedelic companies. This comes...

Friday, September 17, 2021, 10:59:00 AM

Aphria: Multiple Analysts Raise Price Targets Following Q2 2021 Results

Yesterday, Aphria Inc (TSX: APHA) (NASDAQ: APHA) reported its second quarter financial results for fiscal...

Friday, January 15, 2021, 09:33:18 AM

Uber: Consensus Q2 Estimates Point To $3.74 Billion In Revenue

Uber (NYSE: UBER) will be reporting its second quarter financial results after the market close...

Wednesday, August 4, 2021, 02:02:00 PM

Teladoc Sees Consensus Estimates Come Crashing Down After Awful Q1 Results

Last night, Teladoc Health (NYSE: TDOC) confirmed that the pandemic is seemingly over, after seeing...

Thursday, April 28, 2022, 03:41:00 PM